Evidence map›Paper›PMID 37101280›Full record

ReviewJournal of nanobiotechnology2023

Electrochemical aptasensor based on the engineered core-shell MOF nanostructures for the detection of tumor antigens.

Suliman Khan, William C Cho, Afrooz Sepahvand, Sara Haji Hosseinali, Arif Hussain, Mohammad Mahdi Nejadi Babadaei, Majid Sharifi, Mojtaba Falahati, Laila Abdulmohsen Jaragh-Alhadad, Timo L M Ten Hagen and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Suliman KhanMedical Research Center, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
William C ChoDepartment of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China.
Afrooz SepahvandDepartment of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Sara Haji HosseinaliDepartment of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Arif HussainSchool of Life Sciences, Manipal Academy of Higher Education, Dubai, United Arab Emirates.
Mohammad Mahdi Nejadi BabadaeiDepartment of Molecular Genetics, Faculty of Biological Science, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Majid SharifiStudent Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
Mojtaba FalahatiPrecision Medicine in Oncology (PrMiO), Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands. m.falahati@erasmusmc.nl.
Laila Abdulmohsen Jaragh-AlhadadDepartment of Chemistry, College of Science, Kuwait University, 13060, Safat, Kuwait. Laila.alhadad@ku.edu.kw.
Timo L M Ten HagenPrecision Medicine in Oncology (PrMiO), Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands. t.l.m.tenhagen@erasmusmc.nl.
Xin LiDepartment of Neurology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China. lizn99999@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is essential to develop ultrasensitive biosensors for cancer detection and treatment monitoring. In the development of sensing platforms, metal-organic frameworks (MOFs) have received considerable attention as potential porous crystalline nanostructures. Core-shell MOF nanoparticles (NPs) have shown different diversities, complexities, and biological functionalities, as well as significant electrochemical (EC) properties and potential bio-affinity to aptamers. As a result, the developed core-shell MOF-based aptasensors serve as highly sensitive platforms for sensing cancer biomarkers with an extremely low limit of detection (LOD). This paper aimed to provide an overview of different strategies for improving selectivity, sensitivity, and signal strength of MOF nanostructures. Then, aptamers and aptamers-modified core-shell MOFs were reviewed to address their functionalization and application in biosensing platforms. Additionally, the application of core-shell MOF-assisted EC aptasensors for detection of several tumor antigens such as prostate-specific antigen (PSA), carbohydrate antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA), human epidermal growth factor receptor-2 (HER2), cancer antigen 125 (CA-125), cytokeratin 19 fragment (CYFRA21-1), and other tumor markers were discussed. In conclusion, the present article reviews the advancement of potential biosensing platforms toward the detection of specific cancer biomarkers through the development of core-shell MOFs-based EC aptasensors.

Indexed as

Aptamers, NucleotideBiosensing TechniquesMetal-Organic FrameworksNanostructuresAntigens, NeoplasmBiomarkers, TumorHumansKeratin-19Limit of DetectionMaleantigen CYFRA21.1Antigens, NeoplasmAptamers, NucleotideBiomarkers, TumorKeratin-19Metal-Organic FrameworksAptasensorsCancer biomarkersCore-shellMetal organic framework

Identifiers

PMID37101280
PMCPMC10131368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.